Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) The first report of 10-year outcomes of hepatocellular carcinoma treated by percutaneous radio frequency ablation (RFA) indicates that about 1 in 4 patients survive…
NEW YORK (Reuters Health) – For women with breast cancer metastatic to bone, treatment with zoledronic acid to reduce skeletal complications does not prolong progression-free survival or overall…
NEW YORK (Reuters Health) – A large multicenter study confirms that placement of self-expanding metal stents in the colon in cases of malignant colorectal obstruction restores bowel transit…
NEW YORK (Reuters Health) – In recurrent ovarian cancer, combination docetaxel and carboplatin may provide an advantage in terms of progression-free survival (PFS) over sequential docetaxel-carboplatin, according to…
NEW YORK (Reuters Health) – Among patients with early stage non-small-cell lung cancer, treatment with gemcitabine and cisplatin before radical surgery is associated with better survival than is…
NEW YORK (Reuters Health) – Acupuncture given simultaneously with radiotherapy to the head and neck reduces the development and severity of xerostomia (dry mouth) and improves quality of…
NEW YORK (Reuters Health) – When colorectal metastases to the liver are resectable, preoperative chemo is not beneficial. For unresectable lesions, however, chemotherapy to downsize the lesions can…
NEW YORK (Reuters Health) – In selected patients, colectomy can be performed laparoscopically via a single port. However, the advantages of this technique over multiport laparoscopic colectomy seem…
NEW YORK (Reuters Health) – Treatment with the angiotensin receptor blocker (ARB) candesartan is not associated with either carcinogenesis or cancer death compared with non-ARB standard antihypertensive treatment,…
NEW YORK (Reuters Health) – Bone loss in postmenopausal women taking adjuvant letrozole for early breast cancer can be prevented with administration of zoledronic acid, investigators report in…
